Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Yi J, Humphries R, Doerr L, Jerris RC, Westblade LF. Bergeyella zoohelcum Associated with Abscess and Cellulitis After a Dog Bite. Pediatr Infect Dis J. 2016;35(2):214-6.

Marin EP, József L, Di Lorenzo A, Held KF, Luciano AK, Melendez J, et al. The Protein Acyl Transferase ZDHHC21 Modulates α1 Adrenergic Receptor Function and Regulates Hemodynamics. Arterioscler Thromb Vasc Biol. 2016;36(2):370-9.

Hsu Y-, Cushing MM. Autologous Stem Cell Mobilization and Collection. Hematol Oncol Clin North Am. 2016;30(3):573-89.

Zhong Z, Umemura A, Sanchez-Lopez E, Liang S, Shalapour S, Wong J, et al. NF-κB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria. Cell. 2016;164(5):896-910.

Reid MD, Basturk O, Shaib WL, Xue Y, Balci S, Choi H-, et al. Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases. Mod Pathol. 2016;29(10):1243-53.

Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, et al. MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res. 2016;22(4):935-47.

Kumar B, Khaleghzadegan S, Mears B, Hatano K, Kudrolli TA, Chowdhury WH, et al. Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening. Oncotarget. 2016;7(45):72593-72607.

Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet. 2016;48(12):1490-1499.

Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, et al. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016;2(2):165-202.

Gayvert KM, Dardenne E, Cheung C, Boland MR, Lorberbaum T, Wanjala J, et al. A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors. Cell Rep. 2016;15(11):2348-56.